<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="369518">
  <stage>Registered</stage>
  <submitdate>24/10/2015</submitdate>
  <approvaldate>16/02/2016</approvaldate>
  <actrnumber>ACTRN12616000208404</actrnumber>
  <trial_identification>
    <studytitle>The effect of intramuscular administration of dexamethasone alone or in combination of hyoscine butylbromide in shortening the duration of induced labour in Primigravida</studytitle>
    <scientifictitle>The effect of intramuscular administration of dexamethasone alone or in combination of hyoscine butylbromide in shortening the duration of induced labour in Primigravida</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>none</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>prolonged labour</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>compare effect of dexamethasone alone or in combination with hyoscine butylbromide on the duration of labour. In group A, 50 women will receive intramuscular 2 ml dexamethasone (8mg) 6 hours before induction of labour then intramuscular 2 ml saline with the beginning of active phase. In group B,50 women will receive intramuscular 2 ml dexamethasone (8mg) 6 hours before induction of labour then intramuscular 2 ml hyoscine butylbromide (40 mg) with the beginning of active phase. induction of labour will be done by using the following protocol; 2.5 mIU/min of oxytocin intravenous drip (in 500 mL lactated Ringers solution), with the dose increased by 2.5 mIU/ml every 20min till labour Establishment</interventions>
    <comparator>In group C (control group), 50 women will receive two intramuscular saline injections (2 mL)  6 hours hours before induction of labour &amp; with the beginning of active phase.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: Drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>the duration of latent phase of 1st stage of labour
</outcome>
      <timepoint>from the onset of regular uterine contraction (2-3) till beginning of active phase (defined as fully effaced cervix with 3-4 cm dilatation) . outcome will be assessed using partogram record of each patient </timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>the duration of active phase of 1st stage of labour</outcome>
      <timepoint>from fully effaced cervix with 3-4 cm dilatation till fully dilated cervix. outcome will be assessed using partogram record of each patient </timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>mode of delivery</outcome>
      <timepoint>child birth. outcome will be assessed by reviewing hospital record of each patient </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Apgar score at 1 &amp; 5 minutes</outcome>
      <timepoint>immediately after child birth &amp; 5 minutes later. outcome will be assessed by reviewing hospital records.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>primigravidas with singleton living healthy fetus undergo induction of labour,gestational age 38 to 41+6 weeks (confirmed by a reliable date for the last menstrual period and 1st trimester ultrasound scan), vertex presentation of the fetus, favorable cervix (Bishop Score EQUAL TO 7) &amp; intact membranes</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>35</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>Women who had chronic or pregnancy induced diseases or any contraindication to vaginal delivery (e.g. malpresentation, contracted pelvis &amp; placenta previa), the maternal use of drugs (apart from nutritional supplementation), abnormal vaginal bleeding upon pelvic examination, abnormal fetal growth (IUGR or macrosomia), non-reassuring initial fetal CTG, presence of regular uterine contractions (3/10 mins.), uterine scar or anomalies, oligohydramnios (AFI &lt; 5th percentile) &amp; epidural analgesia.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>False</masking2>
    <masking3>False</masking3>
    <masking4>False</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>15/03/2016</anticipatedstartdate>
    <actualstartdate>15/03/2016</actualstartdate>
    <anticipatedenddate>15/09/2016</anticipatedenddate>
    <actualenddate>15/10/2016</actualenddate>
    <samplesize>150</samplesize>
    <actualsamplesize>128</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>20/10/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Egypt</country>
      <state>cairo</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>moutaz mahmoud elsherbini</primarysponsorname>
    <primarysponsoraddress>home address: 26 A el-mekyass st. el roda el-manyal (cairo Egypt)
work address: faculty of medicine - Cairo university ( 109 elmalek elsalah st. post code  11559</primarysponsoraddress>
    <primarysponsorcountry>Egypt</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Self funded/Unfunded</fundingtype>
      <fundingname>moutaz mahmoud elsherbini</fundingname>
      <fundingaddress>home address: 26 A el-mekyass st. el roda el-manyal (cairo Egypt)
work address: faculty of medicine - Cairo university ( 109 elmalek elsalah st. post code  11559</fundingaddress>
      <fundingcountry>Egypt</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Objective: To evaluate the impact of intramuscular (IM) dexamethasone alone or in combination of hyoscine butylbromide (HBB) on the duration of induced labour in Primigravida.
Study Design: A randomized Single-blind placebo controlled study.
Setting: The Obstetrics and Gynecology casuality department of Kasr El Aini hospital (Cairo University). 
Methodology: 150 primigravidas with singleton living healthy fetus undergo induction of labour (IOL) will be enrolled in the study. They will be randomized into 3 groups: group A in which 50 women received IM dexamethasone (8mg) 6 hours before IOL then IM 2 ml saline with the beginning of active phase, group B in which 50 women received IM dexamethasone (8mg) 6 hours before IOL then IM HBB (40 mg) with the beginning of active phase &amp; group C (control group) in which 50 women received two IM saline injections (2 mL) 6 hours before IOL &amp; with the beginning of active phase.
For all patients, full history will be taken followed by complete physical examination &amp; obstetric ultrasound. IOL will be done by using the following protocol; 2.5 mIU/min of oxytocin intravenous drip (in 500 mL lactated Ringers solution), with the dose increased by 2.5 mIU/ml every 20min till labour Establishment. Only patients will be blinded to the contents of syringes. Amniotomy will be done at cervical dilatation equal to 6 cm if spontaneous rupture of membranes does not occur. Participants will be monitored in bed together with fetal wellbeing surveillance using continuous CTG monitoring. A partogram will be maintained throughout labour and vaginal examinations will be conducted &amp; recorded every 2 hours. primary outcomes will include comparing the duration of the latent phase of labour &amp; the duration of active phase of labour among the three groups. 
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>faculty of medicine ethical committee (Cairo university)</ethicname>
      <ethicaddress>elkasr elaini hospital- faculty of medicine -  Cairo university ( 109 elmalek elsalah st. post code  11559) </ethicaddress>
      <ethicapprovaldate>27/09/2015</ethicapprovaldate>
      <hrec>1804268</hrec>
      <ethicsubmitdate>13/09/2015</ethicsubmitdate>
      <ethiccountry>Egypt</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>moutaz mahmoud elsherbini</name>
      <address>home address: 26 A el-mekyass st. el roda el-manyal (cairo Egypt)
work address: faculty of medicine - Cairo university ( 109 elmalek elsalah st. post code  11559</address>
      <phone>+201001588300</phone>
      <fax />
      <email>mizosherbini@yahoo.com</email>
      <country>Egypt</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>moutaz mahmoud elsherbini</name>
      <address>home address: 26 A el-mekyass st. el roda el-manyal (cairo Egypt)
work address: faculty of medicine - Cairo university ( 109 elmalek elsalah st. post code  11559</address>
      <phone>+201001588300</phone>
      <fax />
      <email>mizosherbini@yahoo.com</email>
      <country>Egypt</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>moutaz mahmoud elsherbini</name>
      <address>home address: 26 A el-mekyass st. el roda el-manyal (cairo Egypt)
work address: faculty of medicine - Cairo university ( 109 elmalek elsalah st. post code  11559</address>
      <phone>+201001588300</phone>
      <fax />
      <email>mizosherbini@yahoo.com</email>
      <country>Egypt</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>